SCHEMBL313120

SCHEMBL313120

COc1ccc2c(c1Cl)NC(=O)C2=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 8/20 0.61
L3MBTL1 Q9Y468 1/20 0.54
DAO P14920 2/20 0.47
NSD2 O96028 1/20 0.47
BCHE P06276 1/20 0.47
KDM4E B2RXH2 2/20 0.43
MAPT P10636 2/20 0.43
S1PR4 O95977 1/20 0.43
HSP90AA1 P07900 1/20 0.43
G6PD P11413 1/20 0.43
S1PR1 P21453 1/20 0.43
MAPK1 P28482 1/20 0.43
OPRK1 P41145 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
MCL1 Q07820 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3083667 0.81 CES1 (0.59) CES1L3MBTL1DAONSD2BCHE
SCHEMBL28149043 0.81 L3MBTL1 (0.55) CES1L3MBTL1DAONSD2BCHE
SCHEMBL30615182 0.81 L3MBTL1 (0.55) CES1L3MBTL1DAONSD2BCHE
SCHEMBL1097120 0.81 L3MBTL1 (0.55) CES1L3MBTL1DAONSD2BCHE
SCHEMBL29091601 0.79 L3MBTL1 (0.54) CES1L3MBTL1DAONSD2BCHE
SCHEMBL30615113 0.79 L3MBTL1 (0.54) CES1L3MBTL1DAONSD2BCHE
SCHEMBL3080757 0.77 CES1 (0.67) CES1L3MBTL1DAONSD2BCHE
SCHEMBL15845988 0.76 CES1 (0.62) CES1L3MBTL1DAONSD2BCHE
SCHEMBL30615199 0.76 CES1 (0.62) CES1L3MBTL1DAONSD2BCHE
SCHEMBL1248801 0.76 CES1 (1.00) CES1DAONSD2BCHEMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116925100-A Substituted thiophenoquinolinone compound and preparation method and application thereof 深圳信立泰药业股份有限公司 2023-10-24 CN disclosed
EP-2250174-B1 MACROCYCLIC SERINE PROTEASE INHIBITORS IDENIX PHARMACEUTICALS INC (US) 2013-08-28 EP disclosed
US-8093379-B2 Macrocyclic serine protease inhibitors IDENIX PHARMACEUTICALS, INC. (US) 2012-01-10 US disclosed
US-8003659-B2 Macrocyclic serine protease inhibitors INDENIX PHARMACEUTICALS, INC. (US) 2011-08-23 US disclosed
EP-2250174-A2 MACROCYCLIC SERINE PROTEASE INHIBITORS IDENIX Pharmaceuticals, Inc. (US) 2010-11-17 EP disclosed
US-20100016578-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS IDENIX PHARMACEUTICALS, INC. (US) 2010-01-21 US disclosed
WO-2009099596-A2 MACROCYCLIC SERINE PROTEASE INHIBITORS IDENIX PHARAMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090202480-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS IDENIX PHARMACEUTICALS, INC. (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090202480-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS SERPINB1, SPINT2, PRSS1 CES1 105/4885L3MBTL1 2978/4885DAO 1436/4885
US-20100016578-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS SERPINB1, SPINT2, PRSS1 CES1 105/4885L3MBTL1 2978/4885DAO 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.